271 related articles for article (PubMed ID: 37623461)
1. Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.
Menotti S; Giampietro A; Raia S; Veleno M; Angelini F; Tartaglione T; Gaudino S; Doglietto F; De Marinis L; Pontecorvi A; Bianchi A; Chiloiro S
J Pers Med; 2023 Jul; 13(8):. PubMed ID: 37623461
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
3. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.
Fukuda I
J Nippon Med Sch; 2023 May; 90(2):149-156. PubMed ID: 36823122
[TBL] [Abstract][Full Text] [Related]
5. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic autoimmune hypophysitis: An emerging concept.
Bando H; Kanie K; Takahashi Y
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101601. PubMed ID: 34876362
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
Quandt Z; Kim S; Villanueva-Meyer J; Coupe C; Young A; Kang JH; Yazdany J; Schmajuk G; Rush S; Ziv E; Perdigoto AL; Herold K; Lechner MG; Su MA; Tyrrell JB; Bluestone J; Anderson M; Masharani U
J Endocr Soc; 2023 Feb; 7(4):bvad012. PubMed ID: 36860908
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic autoimmune hypophysitis: a novel form of paraneoplastic endocrine syndrome.
Takahashi Y
Endocr J; 2023 Jun; 70(6):559-565. PubMed ID: 37045779
[TBL] [Abstract][Full Text] [Related]
9. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
10. Recent insights into the pathogenesis of autoimmune hypophysitis.
Frasca F; Piticchio T; Le Moli R; Malaguarnera R; Campennì A; Cannavò S; Ruggeri RM
Expert Rev Clin Immunol; 2021 Nov; 17(11):1175-1185. PubMed ID: 34464545
[TBL] [Abstract][Full Text] [Related]
11. Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients.
Chiloiro S; Capoluongo ED; Tartaglione T; Bianchi A; Giampietro A; Angelini F; Arena V; Pontecorvi A; De Marinis L
Clin Endocrinol (Oxf); 2018 May; 88(5):692-699. PubMed ID: 29418012
[TBL] [Abstract][Full Text] [Related]
12. Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
Chiloiro S; Giampietro A; Bianchi A; Menotti S; Angelini F; Tartaglione T; Antonini Cappellini GC; De Galitiis F; Rossi E; Schinzari G; Scoppola A; Pontecorvi A; De Marinis L; Fleseriu M
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983597
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis: a new aspect of paraneoplastic autoimmune condition.
Urai S; Iguchi G; Kanie K; Bando H; Yamamoto M; Oi Y; Kashitani Y; Iida K; Kanzawa M; Fukuoka H; Takahashi M; Shintani Y; Ogawa W; Takahashi Y
Eur J Endocrinol; 2024 Jan; 190(1):K1-K7. PubMed ID: 38146732
[TBL] [Abstract][Full Text] [Related]
14. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
Deligiorgi MV; Liapi C; Trafalis DT
Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
[TBL] [Abstract][Full Text] [Related]
15. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
Di Dalmazi G; Ippolito S; Lupi I; Caturegli P
Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671
[No Abstract] [Full Text] [Related]
16. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
17. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
Iwama S; De Remigis A; Callahan MK; Slovin SF; Wolchok JD; Caturegli P
Sci Transl Med; 2014 Apr; 6(230):230ra45. PubMed ID: 24695685
[TBL] [Abstract][Full Text] [Related]
18. Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis.
Tartaglione T; Chiloiro S; Laino ME; Giampietro A; Gaudino S; Zoli A; Bianchi A; Pontecorvi A; Colosimo C; De Marinis L
Pituitary; 2018 Aug; 21(4):414-424. PubMed ID: 29752700
[TBL] [Abstract][Full Text] [Related]
19. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.
Kotwal A
Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):427-434. PubMed ID: 34183541
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
